New hope for kids with severe epilepsy: experimental drug ION337 enters human trials
NCT ID NCT07531745
First seen Apr 19, 2026 · Last updated May 24, 2026 · Updated 9 times
Summary
This study tests a new medicine called ION337 in 32 children aged 2 to 12 with Dravet syndrome, a severe form of epilepsy. The main goal is to see if the drug is safe and tolerable when given as a spinal injection. Researchers will also measure how the drug moves through the body and whether it helps reduce major seizures.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRAVET SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Le Bonheur Children's Hospital
RECRUITINGMemphis, Tennessee, 38103, United States
-
Mayo Clinic
RECRUITINGRochester, Minnesota, 55905, United States
-
University of Michigan Health System
RECRUITINGAnn Arbor, Michigan, 48109, United States
Conditions
Explore the condition pages connected to this study.